Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice

Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice

The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The conference featured in-depth discussions on key topics including early prostate cancer screening and precision diagnosis, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive care throughout the disease course.
Pujiang Prostate Cancer Conference | Prof. Yong Yang: The Predictive Value of Deep PSA Response and Treatment Optimization in mHSPC

Pujiang Prostate Cancer Conference | Prof. Yong Yang: The Predictive Value of Deep PSA Response and Treatment Optimization in mHSPC

The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The meeting brought together leading experts in uro-oncology from across China to showcase advances in standardized prostate cancer management and cutting-edge research.
ASCO China Voice | Professors Claudio Vernieri & Man Li: PALMARES-2 Highlights the Potential of CDK4/6 Inhibitor Beyond Progression and Combined Local Therapy

ASCO China Voice | Professors Claudio Vernieri & Man Li: PALMARES-2 Highlights the Potential of CDK4/6 Inhibitor Beyond Progression and Combined Local Therapy

At the 2026 ASCO Annual Meeting, Professor Claudio Vernieri from the Fondazione IRCCS Istituto Nazionale dei Tumori (Italy) presented the key findings of the PALMARES-2 study. Among patients with HR+/HER2− metastatic breast cancer, only about 20% continued first-line endocrine therapy (ET) plus a CDK4/6 inhibitor beyond first progression, achieving a median real-world progression-free survival (rwPFS) of 10.5 months and a median real-world overall survival (rwOS) of 71.3 months. The study also suggested that adding local treatment—particularly radiotherapy—was associated with improved outcomes.
Rethinking the Limits of Flexible Ureteroscopy — An Interview with Prof. John D. Denstedt

Rethinking the Limits of Flexible Ureteroscopy — An Interview with Prof. John D. Denstedt

As the prevalence of kidney stones continues to rise and complex stone disease becomes increasingly common, there is growing demand for minimally invasive, effective, and safe treatment strategies. Flexible ureteroscopy has become a cornerstone of upper urinary tract stone management; however, its role in treating large stone burdens, infection-related stones, and anatomically complex cases remains a subject of debate. Meanwhile, advances such as laser lithotripsy, single-use ureteroscopes, and suction-assisted access sheaths continue to expand treatment possibilities. Balancing maximal stone clearance with minimal complications remains one of the key challenges in modern endourology.
Samsung Breast Cancer Forum | Benlong Yang: Building on Clinical Practice, Embracing Innovation, and Empowering the Next Generation of Breast Cancer Specialists

Samsung Breast Cancer Forum | Benlong Yang: Building on Clinical Practice, Embracing Innovation, and Empowering the Next Generation of Breast Cancer Specialists

The Samsung Breast Cancer Forum, a national meeting bringing together young breast cancer specialists from China's four leading academic breast cancer organizations, was recently held in Zhengzhou. The conference featured a comprehensive scientific program focused on advances in precision breast cancer care, multidisciplinary collaboration, and the development of future clinical leaders.
23rd World Congress on Breast Healthcare | Xin Wang: Advancing Microsurgery to Improve the Quality of Breast Cancer Care

23rd World Congress on Breast Healthcare | Xin Wang: Advancing Microsurgery to Improve the Quality of Breast Cancer Care

Breast cancer remains the most commonly diagnosed malignancy among women worldwide. With advances in early detection and multidisciplinary treatment, five-year survival rates have improved significantly. At the same time, increasing numbers of patients are seeking better postoperative quality of life and breast reconstruction options.
23rd World Congress on Breast Healthcare | Xiaojing Guo: Digital Pathology and AI Are Advancing Precision Breast Cancer Care While China’s Experience Helps Shape Global Standards

23rd World Congress on Breast Healthcare | Xiaojing Guo: Digital Pathology and AI Are Advancing Precision Breast Cancer Care While China’s Experience Helps Shape Global Standards

Breast cancer is the most commonly diagnosed malignancy among women worldwide, and its management has fully entered the era of precision medicine driven by molecular subtyping. Compared with Western populations, Chinese patients tend to develop breast cancer at a younger age and often present with higher-risk disease. Combined with China's large patient population, these characteristics place increasing demands on the efficiency, standardization, and precision of breast pathology.
ASCO China Voice | Zhimin Shao, Zhonghua Wang, and Yin Liu: FUTURE2.0 Study Highlights Novel Combination Strategy for BLIS Triple-Negative Breast Cancer

ASCO China Voice | Zhimin Shao, Zhonghua Wang, and Yin Liu: FUTURE2.0 Study Highlights Novel Combination Strategy for BLIS Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes due to the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, leaving patients without effective endocrine or anti-HER2 targeted therapies. Among its molecular subtypes, basal-like immune-suppressed (BLIS) TNBC is particularly challenging because of its highly invasive biology, immunosuppressive tumor microenvironment, poor response to immunotherapy, and limited treatment options after disease progression.